Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
RCT (n=432) found that, after a median follow up of 39.6 months, patients given venetoclax plus obinutuzumab had a significantly longer progression-free survival than those given chlorambucil plus obinutuzumab (not reached vs 35.6 months, HR 0.31, 95%CI 0.22–0.44).
Source:
The Lancet Oncology
SPS commentary:
A related article comments on this research, and summarises other recent developments in treatment options for this condition. It states that data from other cohorts show high rates of response and durable disease control with Bruton tyrosine kinase inhibitors for disease refractory to venetoclax. The commentary concludes that despite the unanswered questions with respect to optimal treatment sequence, this updated report provides clinicians with an increased confidence that time limited venetoclax plus obinutuzumab is among the range of highly effective frontline treatment options available for patients with chronic lymphocytic leukaemia.